Precision Peptide Company Accounts Payable

The latest accounts payable for BPC.CN is $400K as of July 2026. That compares with $300K in the prior-year period — up 32.4% year over year. Investors often review this figure alongside Precision Peptide Company's historical trend and sector peers before judging valuation or financial health.

Over the past year, BPC.CN's accounts payable moved from $300K to $400K — a 32.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Precision Peptide Company's operating scale or balance-sheet position.

A accounts payable figure of $400K for BPC.CN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BPC.CN's accounts payable ($400K), review year-over-year change from $300K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.